Evidence map›Paper›PMID 35678621›Full record

ArticleFuture oncology (London, England)2022

Solid cancer patients achieve adequate immunogenicity and low rate of severe adverse events after SARS-CoV-2 vaccination.

Urska Janzic, Urska Bidovec-Stojkovic, Katja Mohorcic, Loredana Mrak, Nina Fokter Dovnik, Marija Ivanovic, Maja Ravnik, Marina Caks, Erik Skof, Jerneja Debeljak and 2 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Future oncology (London, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Urska JanzicDepartment of Medical Oncology, University Clinic of Respiratory & Allergic Diseases Golnik, Golnik, 4204, Slovenia.ORCID 0000-0001-9232-1431
Urska Bidovec-StojkovicLaboratory for Clinical Immunology & Molecular Genetics, University Clinic of Respiratory & Allergic Diseases Golnik, Golnik, 4204, Slovenia.
Katja MohorcicDepartment of Medical Oncology, University Clinic of Respiratory & Allergic Diseases Golnik, Golnik, 4204, Slovenia.
Loredana MrakDepartment of Medical Oncology, University Clinic of Respiratory & Allergic Diseases Golnik, Golnik, 4204, Slovenia.
Nina Fokter DovnikDepartment of Oncology, University Medical Centre Maribor, Maribor, 2000, Slovenia.
Marija IvanovicDepartment of Oncology, University Medical Centre Maribor, Maribor, 2000, Slovenia.
Maja RavnikDepartment of Oncology, University Medical Centre Maribor, Maribor, 2000, Slovenia.
Marina CaksDepartment of Oncology, University Medical Centre Maribor, Maribor, 2000, Slovenia.
Erik SkofDepartment of Medical Oncology, Institute of Oncology Ljubljana, Ljubljana, 1000, Slovenia.
Jerneja DebeljakLaboratory for Clinical Immunology & Molecular Genetics, University Clinic of Respiratory & Allergic Diseases Golnik, Golnik, 4204, Slovenia.
Peter KorosecLaboratory for Clinical Immunology & Molecular Genetics, University Clinic of Respiratory & Allergic Diseases Golnik, Golnik, 4204, Slovenia.
Matija RijavecLaboratory for Clinical Immunology & Molecular Genetics, University Clinic of Respiratory & Allergic Diseases Golnik, Golnik, 4204, Slovenia.
University Clinical Centre Maribor · SIUniversity Clinic of Pulmonary and Allergic Diseases Golnik · SIUniversity of Ljubljana · SI

Funding

Javna Agencija za Raziskovalno Dejavnost RS Grant no. P3-0360
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

COVID-19COVID-19 VaccinesImmunogenicity, VaccineNeoplasmsAntibodies, ViralHumansImmunoglobulin GSARS-CoV-2VaccinationAntibodies, ViralCOVID-19 VaccinesImmunoglobulin Ganticancer treatmentimmunogenicitymRNA-based vaccinationseroconversionsolid cancer

Identifiers

PMID35678621
PMCPMC9245563
OpenAlexW4281731767

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.